Search

Your search keyword '"Garg, Anurag"' showing total 511 results
Start Over Author "Garg, Anurag"
511 results on '"Garg, Anurag"'

8. Design and Performance Analysis of PLA-Based Spacer of Artificial Knee Joint Using FEA

Author

Dubey, Divyansh, Narwariya, Manoj, Garg, Anurag, Singh, Rajeev, Singh, Ranjit, Verma, Vijay, Chaari, Fakher, Series Editor, Gherardini, Francesco, Series Editor, Ivanov, Vitalii, Series Editor, Cavas-Martínez, Francisco, Editorial Board Member, di Mare, Francesca, Editorial Board Member, Haddar, Mohamed, Editorial Board Member, Kwon, Young W., Editorial Board Member, Trojanowska, Justyna, Editorial Board Member, Xu, Jinyang, Editorial Board Member, Sethuraman, Balaguru, editor, Jain, Pushpdant, editor, and Gupta, Manoj, editor

Published
2023
Full Text
View/download PDF

9. The Impact of Baseline Intraocular Pressure on Initial Treatment Response in the LiGHT Trial: Selective Laser Trabeculoplasty versus Medication

Author

Adeleke, Mariam, Ambler, Gareth, Barton, Keith, Bourne, Rupert, Broadway, David, Bunce, Catey, Buszewicz, Marta, Crabb, David, Davis, Amanda, Garg, Anurag, Garway-Heath, David, Gazzard, Gus, Hornan, Daniel, Hunter, Rachael, Jayaram, Hari, Jiang, Yuzhen, Konstantakopoulou, Evgenia, Lim, Sheng, Liput, Joanna, Manners, Timothy, Montesano, Giovanni, Morris, Stephen, Nathwani, Neil, Ometto, Giovanni, Rubin, Gary, Strouthidis, Nicholas, Vickerstaff, Victoria, Wilson, Sarah, Wormald, Richard, Wright, David, Zhu, Haogang, and Fahy, Eamonn T.

Published
2024
Full Text
View/download PDF

13. Clinical and patient-reported outcomes of primary selective laser trabeculoplasty in open angle glaucoma & ocular hypertension

Author

Garg, Anurag

Subjects
617.7
Abstract

Aims To investigate the clinical efficacy of primary selective laser trabeculoplasty (SLT) as initial therapy in newly-diagnosed treatment-naïve open-angle-glaucoma (OAG)/ ocular hypertension (OHT) patients. To also investigate patient-reported outcome measures related to health-related quality of life (HRQL) between primary SLT and topical medication. Methods Pre-specified and post-hoc analyses performed using data derived from the Laser in Glaucoma and Ocular Hypertension ('LiGHT') Trial, a multi-centre randomised-controlled trial. Results 718 patients (1235 eyes) were randomised: 356 patients (613 eyes) were allocated to SLT (Laser-1st pathway) and 362 patients (622 eyes) to medical treatment (Medicine-1st pathway). Early absolute IOP-lowering following primary SLT was no different between OHT and OAG eyes (adjusted mean difference = -0.05mmHg; 95% confidence interval (CI) -0.6 to 0.5mmHg; p=0.85). No difference was noted in early absolute IOP-lowering between topical medication and primary SLT (adjusted mean difference = -0.1mmHg; 95% CI, -0.6 to 0.4mmHg; p=0.67). At 36-months, 536 eyes (87.7% of 611 eyes) of 314 patients (88.5% of 355 patients) were available for analysis in Laser-1st pathway. 74.6% of eyes (400 eyes) treated with primary SLT achieved drop-free "disease-control" at 36-months; 58.2% (312 eyes) following single SLT. 6 eyes of 6 patients experienced immediate post-laser IOP spike with 1 eye requiring treatment. 115 eyes of 90 patients received repeat SLT during the first 18 months of the trial. Repeat treatment maintained drop-free IOP control in 67% of these eyes for a subsequent 18 months, with no clinically-relevant adverse events. At 36-months, there was no significant difference in all HRQL measures between the treatment arms, including EQ-5D-5L (adjusted mean difference = 0.01; 95% CI, -0.01 to 0.03; p=0.23). Conclusions This work supports primary SLT to be a safe and clinically effective alternative to topical treatment that could be offered as a first-line IOP lowering treatment to patients with OAG or OHT.

Published
2021

17. Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial: Six-Year Results of Primary Selective Laser Trabeculoplasty versus Eye Drops for the Treatment of Glaucoma and Ocular Hypertension

Author

Adeleke, Mariam, Ambler, Gareth, Barton, Keith, Bourne, Rupert, Broadway, David, Bunce, Catey, Buszewicz, Marta, Crabb, David, Davis, Amanda, Garg, Anurag, Garway-Heath, David, Gazzard, Gus, Hornan, Daniel, Hunter, Rachael, Jayaram, Hari, Jiang, Yuzhen, Konstantakopoulou, Evgenia, Lim, Sheng, Liput, Joanna, Manners, Timothy, Montesano, Giovanni, Morris, Stephen, Nathwani, Neil, Ometto, Giovanni, Rubin, Gary, Strouthidis, Nicholas, Vickerstaff, Victoria, Wilson, Sarah, Wormald, Richard, Wright, David, and Zhu, Haogang

Published
2023
Full Text
View/download PDF

21. A Dual Band Rectangular Patch Notched Antenna with T- and E-Slots

Author

Gupta, Eshita, Garg, Anurag, Kacprzyk, Janusz, Series Editor, Gomide, Fernando, Advisory Editor, Kaynak, Okyay, Advisory Editor, Liu, Derong, Advisory Editor, Pedrycz, Witold, Advisory Editor, Polycarpou, Marios M., Advisory Editor, Rudas, Imre J., Advisory Editor, Wang, Jun, Advisory Editor, Goyal, Vishal, editor, Gupta, Manish, editor, Trivedi, Aditya, editor, and Kolhe, Mohan L., editor

Published
2021
Full Text
View/download PDF

31. Contributors

Author

Anupoju, Gangagni Rao, primary, Arelli, Vijayalakshmi, additional, Arya, Shashi, additional, Begum, Sameena, additional, Bhat, Sartaj Ahmad, additional, Bhowmik, Ankita, additional, Bhunia, Shantanu, additional, Chakma, Ranjit, additional, Chakma, Sumedha, additional, Challa, Murali Mohan, additional, Chavan, Digambar, additional, Chaudhary, Sangeeta, additional, Paul Choudhury, Shinjini, additional, Cui, Guangyu, additional,  , Dharmendra, additional, Devi, Chaichi, additional, Domínguez, Jorge, additional, Garg, Anurag, additional, Garimella, Ravali, additional, Gaur, Abhishek, additional, Gurjar, Suresh Kumar, additional, Hait, Subrata, additional, Haq, Izharul, additional, Hazarika, Jayeeta, additional, Huang, Kui, additional, Hussain, Chaudhery Mustansar, additional, Juntupally, Sudharshan, additional, Kalamdhad, Ajay S, additional, Kanaujia, Nikita, additional, Kandra, Prameela, additional, Kauser, Heena, additional, Khan, Ramsha, additional, Khwairakpam, Meena, additional, Kondepudi, Lakshmi Mounica, additional, Koraganji, Divya Vani, additional, Kumar, Rakshak, additional, Kumar, Sunil, additional, Kumari, Sareeka, additional, Manyapu, Vivek, additional, Maturi, Krishna Chaitanya, additional, Mukherjee, Joydeep, additional, Parashar, Neha, additional, Pottipati, Suryateja, additional, Prasad, Rajnikant, additional, Pusapati, Shreya, additional, Rupani, Parveen Fatemeh, additional, Saha, Biswanath, additional, Sathyan, Arun, additional, Sharma, Dayanand, additional, Shukla, Saurabh, additional, Singh, Diwakar Kumar, additional, Singh, Jiwan, additional, Singh, Shweta, additional, Sinha, Rajiv K., additional, Srivastava, Abhishek N, additional, TG, Induchoodan, additional, Vishwakarma, Shilpa, additional, Xia, Hui, additional, Yadav, Kunwar D., additional, and Zabed, Hossain M., additional

Published
2022
Full Text
View/download PDF

32. Evaluation of factors predicting response to abiraterone acetate in metastatic castration-resistant prostate cancer: A prospective study.

Author

Kumawat, Ghanshyam, Yadav, SS, Jaiswal, Sanjeev, Sahu, Ramdayal, Garg, Anurag, and Tomar, Vinay

Abstract

Background/Objectives: In the current era, abiraterone acetate is mainstay of the treatment strategies of castration-resistant prostate cancer and proven to prolong overall survival. We aimed to prospectively identify factors associated with duration of response to abiraterone. Patients and methods: All metastatic castration-resistant prostate cancer patients eligible for abiraterone were included in the study from February 2019 till March 2020. All baseline data and potential factors associated recorded and follow-up with prostate-specific antigen (PSA), and required investigations were done at 1 month interval. Duration of PSA response was recorded, and patients were divided in five groups on the basis of duration of response. Univariate and multivariate analyses of potential factors were done, and data analysis was done with SPSS (Statistical Package for the Social Sciences) version 21.0. Results: In this study, after univariate analysis, seven factors were associated with longer duration of response to abiraterone. These were PSA at diagnosis (hazard ratio (HR) = −1.011 (95% confidence interval (CI) = 1.003–1.020), p -value = 0.008), PSA at start of abiraterone (HR = −1.018 (95% CI = 1.011–1.025), p -value = 0.0001), nadir PSA (HR = −1.063 (95% CI = 1.024–1.104), p -value = 0.001), prostate-specific antigen doubling (PSAD) time (HR = −0.745 (95% CI = 0.672–0.827), p -value = 0.001), raised alkaline phosphatase (ALP) (HR = −1.002 (95% CI = 1.001–1.003), p -value = 0.001), neutrophil/lymphocyte ratio (NLR) (HR = −2.16 (95% CI = 1.672–2.81), p -value = 0.001) and <5 bone metastasis (HR = −0.235 (95% CI = 0.130–0.422), p -value = 0.01). But after multivariate analysis, nadir PSA achieved, PSAD, NLR and ⩽5 bone metastasis were predictors of better response to abiraterone. Conclusion: This study had identified that less nadir PSA achieved, long PSAD time, low NLR and limited number of skeletal metastases were potential factors for better PSA response to abiraterone. Level of evidence: 1 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. The Association of Brixia Scoring with the Clinical Severity and Need for Invasive Ventilation in Covid-19 Pneumonia Patients - A Prospective Cross-sectional Study.

Author

Narayan, Ashok, Sen, Debraj, J., Reshma, Kumar, Praveen, Goe, Rahul, Garg, Anurag, and Dhagat, Brig P. K.

Subjects
COVID-19, RESOURCE-limited settings, OXYGEN saturation, RURAL hospitals, INTUBATION
Abstract

Imaging is essential for managing COVID-19 pneumonia. In resource-limited settings, chest radiography is the only practicable imaging modality. The Brixia radiographic scoring system, an objective method of assessing pulmonary involvement, is yet to be studied in India. (a) To study the association between the clinical severity of COVID-19 patients with their Brixia scores and, (b) to evaluate the utility of the score as a predictor for invasive ventilation. Peripheral rural hospital by Indian Armed Forces; Cross-sectional study. A thousand patients diagnosed with COVID-19 and hospitalized were classified as having a mild, moderate, and severe disease based on their least oxygen saturation (SpO2 >94: mild, between 90-94: moderate, and <90: severe) recorded. The highest Brixia score was calculated for each patient. The mean Brixia scores of the three groups were compared. The Brixia score of each intubated patient was calculated as was the mean score of all intubated patients. Statistical analysis was performed on SPSS software. Seven hundred fifty-six (756) patients were classified as mild, 104 as moderate, and 140 as severe with a mean Brixia score of 0.12, 2.35, and 10.9, with a standard deviation of 0.66, 2.98, and 2.66, respectively. The difference in means between these groups was statistically significant (p < 0.0001). The median Brixia score of 13 for the intubated patients was significantly higher than for the non-intubated. The clinical severity of the patients and their requirement for invasive ventilation correlated well with their Brixia scores. The Brixia system may be usefully incorporated into our Medicare systems. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Visual Field Outcomes from the Multicenter, Randomized Controlled Laser in Glaucoma and Ocular Hypertension Trial (LiGHT)

Author

Adeleke, Mariam, Ambler, Gareth, Barton, Keith, Bourne, Rupert, Broadway, David, Bunce, Catey, Buszewicz, Marta, Crabb, David, Davis, Amanda, Garg, Anurag, Garway-Heath, David, Gazzard, Gus, Hornan, Daniel, Hunter, Rachael, Jayaram, Hari, Jiang, Yuzhen, Konstantakopoulou, Evgenia, Lim, Sheng, Liput, Joanna, Manners, Timothy, Montesano, Giovanni, Morris, Stephen, Nathwani, Neil, Ometto, Giovanni, Rubin, Gary, Strouthidis, Nicholas, Vickerstaff, Victoria, Wilson, Sarah, Wormald, Richard, Wright, David, Zhu, Haogang, Wright, David M., and Crabb, David P.

Published
2020
Full Text
View/download PDF

39. Efficacy of Repeat Selective Laser Trabeculoplasty in Medication-Naive Open-Angle Glaucoma and Ocular Hypertension during the LiGHT Trial

Author

Adeleke, Mariam, Ambler, Gareth, Barton, Keith, Bourne, Rupert, Broadway, David, Bunce, Catey, Buszewicz, Marta, Crabb, David, Davis, Amanda, Garg, Anurag, Garway-Heath, David, Gazzard, Gus, Hornan, Daniel, Hunter, Rachael, Jayaram, Hari, Jiang, Yuzhen, Konstantakopoulou, Evgenia, Lim, Sheng, Liput, Joanna, Manners, Timothy, Montesano, Giovanni, Morris, Stephen, Nathwani, Neil, Ometto, Giovanni, Rubin, Gary, Strouthidis, Nicholas, Vickerstaff, Victoria, Wilson, Sarah, Wormald, Richard, Wright, David, and Zhu, Haogang

Published
2020
Full Text
View/download PDF

43. Contributors

Author

Agrawal, Komal, primary, Anandkumar, J., additional, Banerjee, Aditi, additional, Bergi, Jay, additional, Bharadvaja, Navneeta, additional, Cai, Q.Q., additional, Das, Jayashankar, additional, Datta, Shivika, additional, Dave, Sushma, additional, Deng, S.H., additional, Dhanjal, Daljeet Singh, additional, Garg, Anurag, additional, Ghosh Sachan, Shashwati, additional, Hu, J.Y., additional, Jayasree, Pyla, additional, Jothinathan, L., additional, Kaur, Sukhmanpreet, additional, Khare, Prateek, additional, Kumar, Prashant, additional, Kumar, Vijay, additional, Kumar, Vineet, additional, Kundu, Lal Mohan, additional, Mishra, Sandhya, additional, Ng, H.Y., additional, Ong, S.L., additional, Pandey, Lalit M., additional, Patel, Ratnesh Kumar, additional, Prashanth, V., additional, Rajput, Parth, additional, Ram, Shristi, additional, Remya, Neelancherry, additional, Romero, Romina, additional, Roy, Arpita, additional, Sahariah, Biju Prava, additional, Satapathy, Monalisa, additional, Shah, Maulin P., additional, Shankar, Ravi, additional, Sharan, Shambhoo, additional, Singh, Joginder, additional, Singh, Kshitij, additional, Singh, Simranjeet, additional, Singh, Swati, additional, Tirkey, Sushma Rani, additional, Trivedi, Ratna, additional, Verma, Ayushi, additional, Verma, Pradeep, additional, Verma, Rahul, additional, and Yadu, Aparna, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results